cell free dnas (cfdnas) are small fragments of genomic or mitochondrial dna releasing from cells into the blood stream. the presence of cfdna in the human circulatory system has been shown for the first time in 1948 however, the potential clinical applications of cfdna remained unknown until recent progress in detection and quantification of these molecules by sensitive methods. in this paper, ...

context prenatal testing aims to identify fetal chromosomal and genetic disorders prior to delivery. current invasive procedures such as amniocentesis and chorionic villus sampling (cvs) pose a risk to mother and fetus and such diagnostic procedures are available only to high-risk pregnancies, which limits aneuploidy detection rate. the identification of cell-free fetal dna (cffdna) in maternal ...

cell free dna (cfdna) is a genetic biomarker that is present in serum or plasma in high concentration in many types of cancer. identification of circu-lating cancer related dna molecules in serum or plasma is a non-invasive tool for early diagnosis and prognosis in many cancer patients. for this review, study selection and data extraction were performed by the authors. detection of point mutati...

nowadays, new advances in the use of cell free fetal dna (cffdna) in maternal plasma of pregnant women has provided the possibility of applying cffdna in prenatal diagnosis as a non-invasive method. in contrary to the risks of invasive methods that affect both mother and fetus, applying cffdna is proven to be highly effective with lower risk. one of the applications of prenatal diagnosis is fet...

Background: Current prenatal diagnosis requires invasive testing which carries a 1-4% procedure-related-risk of miscarriage; hence, non-invasive techniques are desired. The recent demonstration of cell-free-fetal-DNA enriched from maternal plasma has opened new possibilities for non-invasive-prenatal-diagnosis of not only genetic-disorders such as β-thalassaemia and haemophilia but also chromos...

Background: Current prenatal diagnosis requires invasive testing which carries a 1-4% procedure-related-risk of miscarriage; hence, non-invasive techniques are desired. The recent demonstration of cell-free-fetal-DNA enriched from maternal plasma has opened new possibilities for non-invasive-prenatal-diagnosis of not only genetic-disorders such as β-thalassaemia and haemophilia but also chromos...